Please ensure Javascript is enabled for purposes of website accessibility

3 Popular Robinhood Stocks Still Worth Buying With the Market at an All-Time High

By Keith Speights – Updated Aug 30, 2020 at 1:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's not too late at all to scoop up shares of these Robinhood favorites.

That major market meltdown in March now seems like ancient history. The stock market roared back and reached record highs last week. That's the good news.

The bad news is that many stocks now sport downright frothy valuations, including a lot of the most popular stocks on the Robinhood trading platform. But don't think you have to stay away from stocks because of the sky-high valuations. Here are three popular Robinhood stocks that are still worth buying even with the market at an all-time high. 

Man holding a smartphone with two computer monitors on his desk

Image source: Getty Images.

1. Berkshire Hathaway

Berkshire Hathaway (BRK.A 0.35%) (BRK.B 0.40%) is one of Robinhood investors' favorite stocks that hasn't fully bounced back from the sell-off earlier this year. But as its chairman and CEO Warren Buffett celebrates his 90th birthday, Berkshire remains a solid stock to buy for long-term investors.

While Berkshire's valuation isn't as low as it was in the first half of 2020, it's still attractive. The conglomerate's shares trade at only 1.3 times book value. 

Arguably one of the best reasons to buy Berkshire is its massive cash stockpile (and what Buffett will do with all that money). As of June 30, 2020, the company had cash, cash equivalents, and U.S. Treasury Bills of $142.8 billion. Berkshire bought back over $5 billion worth of its shares in the first half of the year.

Look for more stock buybacks in the future, which will increase the value of its outstanding shares. When the market falls again (note: it's when not if), Buffett will still have a lot of dry powder to buy other stocks and perhaps even an entire company or two on the cheap.

2. Amazon

Sure,'s (AMZN -0.77%) share price is higher than ever. And yes, the stock trades at a jaw-dropping 116 times expected earnings and over 130 times trailing 12-month earnings. You might think that's a sure-fire sign to stay away. But it's not.

Take a look at the following chart. Amazon stock is actually trading near the low end of its valuation range over the past five years.

AMZN PE Ratio Chart

AMZN PE Ratio data by YCharts

You can pretty much throw earnings-based valuation metrics out the window with Amazon. The e-commerce and cloud computing giant reinvests heavily into opportunities for future growth.

Amazon's business boomed with the coronavirus pandemic. It will likely keep on booming as consumers shop more online and as organizations move their applications and data to the cloud.

The company is expanding its presence in the grocery market with the launch of Amazon Fresh stores. It's going head-to-head with Apple Watch and Fitbit with its new Halo device. Amazon also has new growth opportunities in healthcare and self-driving car technology. This high-flying stock should have a lot more room to run.

3. Novavax

You might be surprised that Novavax (NVAX -2.88%) is on the list. After all, the biotech stock is up a whopping 2,600% year to date. It now sports a market cap of around $7 billion. Novavax doesn't have a product to generate revenue and is a long way from becoming profitable. But the opportunities for Novavax are ginormous. 

The company reported very good results from an early stage clinical study of its COVID-19 vaccine candidate NVX‑CoV2373. Some analysts even project that NVX‑CoV2373 will be better than all of the other coronavirus vaccine candidates currently in clinical testing.

Uncle Sam appears to think highly of the prospects for NVX‑CoV2373, too. In July, Novavax won $1.6 billion in funding from Operation Warp Speed, the U.S. government's initiative to accelerate the development of COVID-19 vaccines.

Novavax is also moving forward with filing for FDA approval for another pipeline candidate, NanoFlu. The experimental flu vaccine beat Sanofi's market-leading FluZone Quadrivalent in a head-to-head late-stage study. If approved, NanoFlu has a good chance of becoming a blockbuster for Novavax. 

To be sure, Novavax is much riskier than Berkshire Hathaway or Amazon. But if clinical testing continues to go well for NVX‑CoV2373, this popular Robinhood stock should be an even bigger winner over the next few years than either of the two giants.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Speights owns shares of Amazon, Apple, and Berkshire Hathaway (B shares). The Motley Fool owns shares of and recommends Amazon, Apple, Berkshire Hathaway (B shares), and Fitbit and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), short January 2022 $1940 calls on Amazon, long January 2022 $1920 calls on Amazon, and short September 2020 $200 calls on Berkshire Hathaway (B shares). The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amazon Stock Quote
$93.41 (-0.77%) $0.72
Berkshire Hathaway (A shares) Stock Quote
Berkshire Hathaway (A shares)
$478,675.55 (0.35%) $1,655.56
Berkshire Hathaway (B shares) Stock Quote
Berkshire Hathaway (B shares)
$317.43 (0.40%) $1.25
Novavax Stock Quote
$16.54 (-2.88%) $0.49
Apple Stock Quote
$148.11 (-1.96%) $-2.96
Sanofi Stock Quote
$45.39 (0.78%) $0.35
Fitbit Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.